Literature DB >> 7511974

Human astrocytes are only partially competent antigen presenting cells. Possible implications for lesion development in multiple sclerosis.

F Weber1, E Meinl, F Aloisi, C Nevinny-Stickel, E Albert, H Wekerle, R Hohlfeld.   

Abstract

Highly purified astrocyte cultures from human embryonic brain were examined for their capacity to present antigen to human leukocyte antigen (HLA) class II compatible, cytolytic CD4+ T lymphocytes. Most astrocytes constitutively expressed HLA class I products and LFA-3 (CD58). Constitutive expression of HLA class II, LFA-1 alpha (CD11a) and ICAM-1 (CD54) was lower and varied among different cultures, while LFA-2 (CD2) was absent. IFN-gamma alone or in combination with TNF-alpha strongly enhanced expression of HLA class I, HLA-DR, -DP, -DQ, LFA-1 alpha and ICAM-1, but did not affect expression of LFA-2 (CD2) and LFA-3 (CD58). TNF-alpha alone induced only HLA class I and ICAM-1, but not HLA class II or LFA-1 alpha. Cytokine treated, but not untreated astrocytes were able to present protein (auto-)antigens to specific T lymphocyte lines. Astrocytes expressing appropriate major histocompatibility complex class II products were lysed by CD4+ T cells specific for myelin basic protein or tetanus toxoid. The lytic response was antigen dose dependent and HLA-DR restricted. It could be blocked by antibodies against HLA-DR determinants and against the adhesion molecules LFA-1 alpha and ICAM-1. In remarkable contrast to their susceptibility to T cell lysis, antigen presenting astrocytes were not only completely unable to induce T cell proliferation but even inhibited proliferation. The results indicate that, although human astrocytes have the potential to present protein antigens to CD4+ T cells, they do not induce the co-stimulatory factors required to trigger the complete T cell activation programme.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511974     DOI: 10.1093/brain/117.1.59

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  14 in total

Review 1.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 2.  Immune players in the CNS: the astrocyte.

Authors:  Cathy J Jensen; Ann Massie; Jacques De Keyser
Journal:  J Neuroimmune Pharmacol       Date:  2013-07-04       Impact factor: 4.147

Review 3.  Pathophysiology of the blood-brain barrier.

Authors:  K Selmaj
Journal:  Springer Semin Immunopathol       Date:  1996

Review 4.  Mechanisms of action of interferon-beta in multiple sclerosis.

Authors:  B G Arnason; A Dayal; Z X Qu; M A Jensen; K Genç; A T Reder
Journal:  Springer Semin Immunopathol       Date:  1996

5.  Distribution of ICAM-1 immunoreactivity during aging in the human orbitofrontal cortex.

Authors:  Jose Javier Miguel-Hidalgo; Sorcha Nithuairisg; Craig Stockmeier; Grazyna Rajkowska
Journal:  Brain Behav Immun       Date:  2006-07-07       Impact factor: 7.217

Review 6.  T-cell cytokines in injury-induced neural damage and repair.

Authors:  Michael Schroeter; Sebastian Jander
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 7.  Astrocytes in multiple sclerosis: a product of their environment.

Authors:  A Nair; T J Frederick; S D Miller
Journal:  Cell Mol Life Sci       Date:  2008-09       Impact factor: 9.261

Review 8.  Immune surveillance of the central nervous system in multiple sclerosis--relevance for therapy and experimental models.

Authors:  Rehana Z Hussain; Liat Hayardeny; Petra C Cravens; Felix Yarovinsky; Todd N Eagar; Benjamine Arellano; Krystin Deason; Cyd Castro-Rojas; Olaf Stüve
Journal:  J Neuroimmunol       Date:  2014-08-30       Impact factor: 3.478

9.  MicroRNAs and Multiple Sclerosis.

Authors:  Kemal Ugur Tufekci; Meryem Gulfem Oner; Sermin Genc; Kursad Genc
Journal:  Autoimmune Dis       Date:  2010-11-11

Review 10.  CD58 Immunobiology at a Glance.

Authors:  Yalu Zhang; Qiaofei Liu; Sen Yang; Quan Liao
Journal:  Front Immunol       Date:  2021-06-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.